Navigation Links
Trubion Announces Presentation of Positive TRU-016 Data at ASCO
Date:6/2/2008

of B-cell malignancies," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "TRU-016 represents a first-in-class product opportunity with an exciting, differentiated pre-clinical profile. The demonstrated ability of TRU-016 to kill tumor cells through powerful apoptotic signaling as well as potent ADCC-mediated activity, combined with its synergy with chemotherapies and anti-CD20 therapies, adds to our confidence that this drug, either alone or in combination with other effective therapies, may offer meaningful benefits to patients with these diseases. We look forward to the results of our ongoing Phase 1/2 clinical trial currently evaluating TRU-016 in CLL patients."

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
2. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
5. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
6. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
7. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
8. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
(Date:10/22/2014)... 21, 2014 Influenza will affect as many as ... the United States as high as 49,000 ... spread is from person to person in respiratory droplets of ... way of death, but kills much fewer people each year ... by human fluids including sweat, saliva, blood and other bodily ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... Mich., June 17 GeneGo, Inc., a leading,provider ... announced,today that they were awarded a Phase I ... of a platform for functional data analysis in,cancer. ... Boston on the project. The system, MetaMiner (Oncology) ...
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
Cached Medicine Technology:GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer 2Pharmaxis Establishes Named Patient Program for Bronchitol 2
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... Sept. 12 Medina General Hospital and,University Hospitals ... of,Understanding in which Medina General has indicated its ... University Hospitals, network of,community- based hospitals. The agreement ... with final regulatory and governance approvals. "We,re ...
... METAIRIE, La., Sept. 12 OrthoSynetics(TM), the largest,provider ... has hired David Ward as Western Region Sales ... to serving our existing,doctors and practices, as well ... Roussos, president and CEO of OrthoSynetics(TM). "He,is yet ...
... Sept. 12 A Sept. 12 signing of ... NASA and the,National Institutes of Health in their ... entered into an agreement that helps,American scientists use ... health and diseases. The pact signals to researchers ...
... Reaches Out to Educate Chicagoans, CHICAGO, Sept. ... empower the people of Chicago, SAVE THE PATIENT, ... show on the Chicago Access Network (CAN-TV). "Community ... PM on CAN-TV, Channel 21., Monday,s program ...
... Youre whale watching in Alaska, longing for a margarita and ... did I get here" I hate the cold. Never finished ... from the Journal of Consumer Research finds that when we ... a wider array of options will sound appealing, potentially leading ...
... Former Food and Drug Administration,commissioners David Kessler and ... new legislation that strengthens prescription drug safety and,revamps ... panelists in a,conference hosted by American University and ... report from Pfizer at:, http://media.medialink.com/WebNR.aspx?story=33842 Registered ...
Cached Medicine News:Health News:Medina General Hospital and University Hospitals Agree to Pursue Affiliation 2Health News:David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager 2Health News:NASA and NIH Partner for Health Research in Space 2Health News:Health Knowledge Empowers the Public 2Health News:Wanting a bite of everything: Hungry people crave more variety 2
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... The ORK WAVEFRONT ANALYZER ... the aberrations of the entire ... ability to analyze aberrations in ... of sphere, cylinder, higher order ...
... eye drops quickly remove redness ... other pollutants and provide protection ... and the sun. This unique ... LIQUIFILM®, to soothe, cool and ...
Medicine Products: